Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population

Pharmacogenetics

Volumn 6, Issue 5, 1996, Pages 441-447

  Roh, Hyung Keun ^a,b   Dahl, Marja Liisa ^a   Johansson, Inger ^c   Ingelman Sundberg, Magnus ^c   Cha, Young Nam ^b   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Inha University School of Medicine   (South Korea)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CYP2C19; CYP2D6; Debrisoquine; Koreans; Mephenytoin; Polymorphism

Indexed keywords

4 HYDROXYDEBRISOQUINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DNA; DRUG METABOLITE; MEPHENYTOIN;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; MALE; MEPHENYTOIN; PHENOTYPE; POINT MUTATION; POLYMORPHISM, GENETIC;

EID: 0029824252     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199610000-00008     Document Type: Article

References (40)

1. Agúndez JA, Ledesma MC, Ladero JM, Benitez, J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995: 57. 265 269.
2. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylalion polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39. 533-537.
3. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYT2D6J and related poly-morphisms in a European population. Pharmacogenetics 1994: 4. 73 81.
4. Bertilsson L, Lou Y-O, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, Wang K-Y, Reviriego J. lselius L. Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992: 51. 388-397.
5. Brusen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995: 5. 312 317.
6. Chang M, Dahl. ML, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylalion phenotype and CYP2C19 genotype. Pharmacogenetics 1995: 5. 358-363.
7. Dahl M-L, Yue Q-Y, Roh H-K, Johansson I, Säwe J, Sjöqvist F, Bertilsson L. Genetic analysis of the CYP2D locus in relation to debrosoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995a: 5, 159-164.
8. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylalion of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Therap 1995b: 274. 516-520.
9. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991: 1, 33-41.
10. Daly AK, Steen VM, Fairbrother KS, Andreasson OA, Idle JR. Characterization of the poor metabolizer associated CYP2D 11 kb RFLP fragment using long PCR. Abstracts of the 9th International Conference on Cytochrome P450 Biochemistry, Biophysics and Molecular Biology, Zurich, 23-27 July 1995. p. 42.
11. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA. Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a:269. 15419-15422.
12. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b: 46. 594-598.
13. de Morais SMF, Goldstein JA, Xie HG. Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N. Zhou H. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995: 58. 404-411.
14. Eichelbuum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979: 16. 183-187.
15. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RI. A family and population study of the genetic polymorphism of debrisoquine oxidation in a while British population. J Med Genet 1980: 17. 102-105.
16. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
17. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-552.
18. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, Liao C-L, Zhang L-M. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989: 46, 198-207.
19. Ingelman-Sundberg M, Johansson I, Persson I, Yue Q-Y, Dahl ML, Bertilsson L, Sjöqvist F. Genetic polymorphism of cytochromes P450: Interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 1992: 2, 264-271.
20. Ishizuki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 1987: 23, 482-485.
21. Johansson I, Yue QY, Dahl M-L, Heim M, Säwe J. Bertilsson L, Meyer UA. Sjöqvist F. Ingelman-Sundberg M. Genetic analysis of the interethnic differences between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991: 40, 553-556.
22. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90. 11825-11829.
23. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelmun-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994: 46, 452-459.
24. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985: 19, 483-487.
25. Lee EJD, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994:37, 605-607.
26. Lennard MS, Silas JH, Smith AJ, Tucker GT. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977: 1997: 133, 161-166.
27. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977: 11, 584-586.
28. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz F, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985: 38, 402-408.
29. Sanz EJ, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989: 45, 495-499.
30. Saha N, Tay JSH. Origin of the Koreans: a population genetic study. Am J Physical Anthropol 1992: 88, 27-36.
31. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P-450 db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988: 85, 5240-5243.
32. Sohn D-R, Shin S-G, Park C-W, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991: 32, 504-507.
33. Sohn D-R, Kusaka M, Ishizaki T, Shin S-G, Jang I-J, Shin J-G, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992: 52, 160-169.
34. Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988: 44, 431-435.
35. Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AI. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977: 2 718.
36. Tybring G, Bertilsson L. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992: 2. 241-243.
37. Wang S-L, Huang J-D, Lai M-D, Liu B-H, Lai M-L. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993: 53, 410-418.
38. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 1984: 307, 121-127.
39. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993: 3, 256-263.
40. Yue QY, Bertilsson L, Dahl-Puustinen ML, Säwe J, Sjöqvist F, Johansson I, Ingelman-Sundberg M. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet 1989: 2, 870.